Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qiagen ( (QGEN) ) has issued an update.
QIAGEN disclosed that the Netherlands Authority for the Financial Markets has notified the company of a substantial shareholding position held by Goldman Sachs Group Inc. in the company. The notification details a mix of ordinary shares, convertible bonds, options, warrants, and swaps, resulting in an overall capital and voting-rights interest of about 2.87% in QIAGEN, signaling a notable institutional stake that may be closely watched by investors.
The company emphasized that it is not responsible for the accuracy of the AFM filing, which is drawn directly from the regulator’s public register. While the announcement is largely technical, the size and structure of Goldman Sachs’ exposure underscores continued institutional engagement with QIAGEN’s stock across multiple markets and instruments, with potential implications for liquidity and trading dynamics.
The most recent analyst rating on (QGEN) stock is a Hold with a $52.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V., based in Venlo, Netherlands, operates in the life sciences and molecular diagnostics industry, providing sample and assay technologies used in research, pharmaceutical development, and clinical testing. Its shares are listed on several European exchanges as well as the NYSE and Swiss markets, reflecting a broad international investor base.
Average Trading Volume: 1,973,130
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.5B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.